Acute mountain sickness

NEW YORK, July 31 (Praxis Press) Several medications have been used to alleviate or prevent acute mountain sickness (AMS), but their relative efficacies are unknown. Dumont and colleagues reviewed 33 randomized placebo-controlled trials of drugs used to prevent AMS. The mean incidence of AMS above 4,000 meters was 67% in subjects taking a placebo; the rate of ascent correlated with incidence, whereas altitude and mode of ascent did not. Dexamethasone (8-16 mg) and acetazolamide (750 mg) prevente


Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

NEW YORK, July 31 (Praxis Press) Several medications have been used to alleviate or prevent acute mountain sickness (AMS), but their relative efficacies are unknown. Dumont and colleagues reviewed 33 randomized placebo-controlled trials of drugs used to prevent AMS. The mean incidence of AMS above 4,000 meters was 67% in subjects taking a placebo; the rate of ascent correlated with incidence, whereas altitude and mode of ascent did not. Dexamethasone (8-16 mg) and acetazolamide (750 mg) prevented AMS (relative risks [RR], 2.50 and 2.18, respectively; number needed to treat, 2.8 and 2.9, respectively). Lower doses of dexamethasone (0.5 or 2 mg) and acetazolamide (500 mg) were ineffective. Dexamethasone was associated with adverse effects upon abrupt discontinuation (RR, 4.45); acetazolamide was associated with parasthesias (RR, 4.02) and polyuria (RR, 4.24). At ascent rates greater than 500 meters/day above 4,000 meters, higher doses of dexamethasone and acetazolamide are equally effective for preventing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development